Zoledronic acid Teva Generics

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
08-08-2016
Summary of Product characteristics Summary of Product characteristics (SPC)
08-08-2016
Public Assessment Report Public Assessment Report (PAR)
08-08-2016

Active ingredient:

монохидрат на золедроновата киселина

Available from:

Teva Generics B.V

ATC code:

M05BA08

INN (International Name):

zoledronic acid

Therapeutic group:

бифосфонати

Therapeutic area:

Osteoporosis; Osteitis Deformans

Therapeutic indications:

Лечение osteoporosisin стълб-menopausal жени за възрастни Менат повишен риск от фрактури, включително и с последните дъна-травми на бедрената кост . Лечение на остеопороза, свързан с дългосрочен системна глюкокортикоидной терапия след менопаузата жените за възрастни Менат повишен риск от фрактури. Лечение на болест на Paget на костите при възрастни.

Product summary:

Revision: 2

Authorization status:

Отменено

Authorization date:

2014-03-27

Patient Information leaflet

                                55
Б. ЛИСТОВКА
Лекарствен продукт с невалидно
разрешение за употреба
56
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
ЗОЛЕДРОНОВА КИСЕЛИНА TEVA GENERICS 5 MG
ИНФУЗИОНЕН РАЗТВОР В БУТИЛКИ
Золедронова киселина (Zoledronic acid)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ВИ БЪДЕ ПРИЛОЖЕНО ТОВА
ЛЕКАРСТВО, ТЪЙ
КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА ВАС
ИНФОРМАЦИЯ.
-
Запазете тази листовка. Може да се
наложи да я прочетете отново.
-
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар,
фармацевт или
медицинска сестра.
-
Ако получите някакви нежелани
лекарствени реакции, уведомете Вашия
лекар,
фармацевт или медицинска сестра. Това
включва и всички възможни нежелани
реакции,
неописани в тази листовка. Вижте точка
4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА
1.
Какво представлява Золедронова
киселина Teva Generics и за какво се
използва
2.
Какво трябва да знаете, преди да Ви
бъде приложена Золедронова киселина
Teva Generics
3.
Как се прилага Золедронова киселина
Teva Generics
4.
Възможни нежелани реакции
5.
Как да съхранявате Золедронова
киселина Teva Generics
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА ЗОЛЕДРОНОВА
КИСЕЛИНА TEVA GENERICS И ЗА КАКВО СЕ
ИЗПОЛЗ
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
Лекарствен продукт с невалидно
разрешение за употреба
2
1.
ИМЕ НА ЛЕКАРСТВЕНИЯ ПРОДУКТ
Золедронова киселина Teva Generics 5 mg
инфузионен разтвор в бутилки
2.
КАЧЕСТВЕН И КОЛИЧЕСТВЕН СЪСТАВ
Всяка бутилка съдържа 5 mg золедронова
киселина
_(zoledronic acid)_
(като монохидрат).
Всеки ml от разтвора съдържа 0,05 mg
золедронова киселина (като
монохидрат).
За пълния списък на помощните
вещества вижте точка 6.1.
3.
ЛЕКАРСТВЕНА ФОРМА
Инфузионен разтвор
Прозрачен и безцветен разтвор.
4.
КЛИНИЧНИ ДАННИ
4.1
ТЕРАПЕВТИЧНИ ПОКАЗАНИЯ
Лечение на остеопороза
•
при жени след менопауза
•
при възрастни мъже
с повишен риск от фрактури,
включително тези, претърпели наскоро
фрактура на бедрената
кост, причинена от минимална травма.
Лечение на остеопороза, свързана с
продължителна системна
глюкокортикоидна терапия
•
при жени след менопауза
•
при възрастни мъже
с повишен риск от фрактури.
Лечение на болест на Paget при възрастни.
4.2
ДОЗИРОВКА И НАЧИН НА ПРИЛОЖЕНИЕ
Дозировка
Преди приложение на золедронова
киселина пациентите трябва да бъдат
достатъчно
хидратирани. Това е от особено
значение при пациенти
                                
                                Read the complete document

Similar products

Active ingredient монохидрат на золедроновата киселина

монохидрат на золедроновата киселина

ATC code M05BA08

M05BA08

Marketed by Teva Generics B.V

Teva Generics B.V

INN (International Name) zoledronic acid

zoledronic acid

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 08-08-2016
Summary of Product characteristics Summary of Product characteristics Spanish 08-08-2016
Public Assessment Report Public Assessment Report Spanish 08-08-2016
Patient Information leaflet Patient Information leaflet Czech 08-08-2016
Summary of Product characteristics Summary of Product characteristics Czech 08-08-2016
Public Assessment Report Public Assessment Report Czech 08-08-2016
Patient Information leaflet Patient Information leaflet Danish 08-08-2016
Summary of Product characteristics Summary of Product characteristics Danish 08-08-2016
Public Assessment Report Public Assessment Report Danish 08-08-2016
Patient Information leaflet Patient Information leaflet German 08-08-2016
Summary of Product characteristics Summary of Product characteristics German 08-08-2016
Public Assessment Report Public Assessment Report German 08-08-2016
Patient Information leaflet Patient Information leaflet Estonian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Estonian 08-08-2016
Public Assessment Report Public Assessment Report Estonian 08-08-2016
Patient Information leaflet Patient Information leaflet Greek 08-08-2016
Summary of Product characteristics Summary of Product characteristics Greek 08-08-2016
Public Assessment Report Public Assessment Report Greek 08-08-2016
Patient Information leaflet Patient Information leaflet English 08-08-2016
Summary of Product characteristics Summary of Product characteristics English 08-08-2016
Public Assessment Report Public Assessment Report English 08-08-2016
Patient Information leaflet Patient Information leaflet French 08-08-2016
Summary of Product characteristics Summary of Product characteristics French 08-08-2016
Public Assessment Report Public Assessment Report French 08-08-2016
Patient Information leaflet Patient Information leaflet Italian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Italian 08-08-2016
Public Assessment Report Public Assessment Report Italian 08-08-2016
Patient Information leaflet Patient Information leaflet Latvian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Latvian 08-08-2016
Public Assessment Report Public Assessment Report Latvian 08-08-2016
Patient Information leaflet Patient Information leaflet Lithuanian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Lithuanian 08-08-2016
Public Assessment Report Public Assessment Report Lithuanian 08-08-2016
Patient Information leaflet Patient Information leaflet Hungarian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Hungarian 08-08-2016
Public Assessment Report Public Assessment Report Hungarian 08-08-2016
Patient Information leaflet Patient Information leaflet Maltese 08-08-2016
Summary of Product characteristics Summary of Product characteristics Maltese 08-08-2016
Public Assessment Report Public Assessment Report Maltese 08-08-2016
Patient Information leaflet Patient Information leaflet Dutch 08-08-2016
Summary of Product characteristics Summary of Product characteristics Dutch 08-08-2016
Public Assessment Report Public Assessment Report Dutch 08-08-2016
Patient Information leaflet Patient Information leaflet Polish 08-08-2016
Summary of Product characteristics Summary of Product characteristics Polish 08-08-2016
Public Assessment Report Public Assessment Report Polish 08-08-2016
Patient Information leaflet Patient Information leaflet Portuguese 08-08-2016
Summary of Product characteristics Summary of Product characteristics Portuguese 08-08-2016
Public Assessment Report Public Assessment Report Portuguese 08-08-2016
Patient Information leaflet Patient Information leaflet Romanian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Romanian 08-08-2016
Public Assessment Report Public Assessment Report Romanian 08-08-2016
Patient Information leaflet Patient Information leaflet Slovak 08-08-2016
Summary of Product characteristics Summary of Product characteristics Slovak 08-08-2016
Public Assessment Report Public Assessment Report Slovak 08-08-2016
Patient Information leaflet Patient Information leaflet Slovenian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Slovenian 08-08-2016
Public Assessment Report Public Assessment Report Slovenian 08-08-2016
Patient Information leaflet Patient Information leaflet Finnish 08-08-2016
Summary of Product characteristics Summary of Product characteristics Finnish 08-08-2016
Public Assessment Report Public Assessment Report Finnish 08-08-2016
Patient Information leaflet Patient Information leaflet Swedish 08-08-2016
Summary of Product characteristics Summary of Product characteristics Swedish 08-08-2016
Public Assessment Report Public Assessment Report Swedish 08-08-2016
Patient Information leaflet Patient Information leaflet Norwegian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Norwegian 08-08-2016
Patient Information leaflet Patient Information leaflet Icelandic 08-08-2016
Summary of Product characteristics Summary of Product characteristics Icelandic 08-08-2016
Patient Information leaflet Patient Information leaflet Croatian 08-08-2016
Summary of Product characteristics Summary of Product characteristics Croatian 08-08-2016
Public Assessment Report Public Assessment Report Croatian 08-08-2016

Search alerts related to this product

Alerts Zoledronic acid Teva Generics монохидрат на золедроновата киселина

Zoledronic acid Teva Generics монохидрат на золедроновата киселина

View documents history

Documents history Documents history

Zoledronic acid Teva Generics